/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Esperion Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.78 0.0328(3.28%) ESPR at 04 Dec 2025 04:31 PM Drug Manufacturers - Specialty & Generic
Lowest Today 3.615
Highest Today 3.84
Today’s Open 3.675
Prev. Close 3.66
52 Week High 4.03
52 Week Low 0.69
Day’s Range: Low 3.615 High 3.84
52-Week Range: Low 0.69 High 4.03
1 day return -
1 Week return -5.25
1 month return +33.21
3 month return +49.21
6 month return +238.39
1 year return +3.26
3 year return -49.36
5 year return -87.42
10 year return -

Institutional Holdings

BlackRock Inc 7.30

Vanguard Group Inc 5.81

Wasatch Advisors LP 5.13

Two Seas Capital LP 4.94

BB Biotech AG Ord 4.93

Wasatch Ultra Growth 3.48

Penderfund Capital Management Ltd 3.31

Pender Corporate Bond F 3.15

Vanguard Total Stock Mkt Idx Inv 3.00

Marshall Wace Asset Management Ltd 2.63

iShares Russell 2000 ETF 2.40

Geode Capital Management, LLC 2.27

State Street Corp 1.86

Indaba Capital Management, LLC 1.49

Citadel Advisors Llc 1.16

Two Sigma Advisers, LLC 1.04

Fidelity Small Cap Index 0.99

Vanguard Institutional Extnd Mkt Idx Tr 0.97

Two Sigma Investments LLC 0.91

Northern Trust Corp 0.88

UBS Group AG 0.76

Woodline Partners LP 0.75

Royal Bank of Canada 0.58

iShares Russell 2000 Value ETF 0.58

Morgan Stanley - Brokerage Accounts 0.52

Vanguard Explorer Inv 0.50

Fidelity Extended Market Index 0.49

Vanguard Russell 2000 ETF 0.47

Susquehanna International Group, LLP 0.41

Bank of America Corp 0.41

Goldman Sachs Group Inc 0.40

State St Russell Sm Cap® Indx SL Cl I 0.32

iShares Russell 2000 Growth ETF 0.29

Schwab Small Cap Index 0.26

NT R2000 Index Fund - NL 0.24

Wasatch Long/Short Alpha Institutional 0.24

iShares Micro-Cap ETF 0.22

Renaissance Global Small Cap 0.21

Wasatch Long Short Alpha Composite 0.20

NT R2000 Index Fund - DC - NL - 3 0.19

Market Status

Strong Buy: 2

Buy: 2

Hold: 2

Sell: 1

Strong Sell: 0

Fundamentals

Market Cap 867.67 M

PB Ratio 98.4236

PE Ratio 0.0

Enterprise Value 1096.25 M

Total Assets 343.82 M

Volume 4149422

Company Financials

Annual Revenue FY23:102902000 102.9M, FY22:75475000 75.5M, FY21:78447000 78.4M, FY20:227547000 227.5M, FY19:148364000 148.4M

Annual Profit FY23:66927000 66.9M, FY22:48508000 48.5M, FY21:64230000 64.2M, FY20:225155000 225.2M, FY19:148364000 148.4M

Annual Net worth FY23:-208391000 -208.4M, FY22:-287817000 -287.8M, FY21:-318824000 -318.8M, FY20:-166189000 -166.2M, FY19:-109022000 -109.0M

Quarterly Revenue Q3/2025:87309000 87.3M, Q2/2025:82385000 82.4M, Q1/2025:64995000 65.0M, Q3/2024:51632000 51.6M, Q2/2024:73834000 73.8M

Quarterly Profit Q3/2025:31889000 31.9M, Q2/2025:53842000 53.8M, Q1/2025:33457000 33.5M, Q3/2024:34346000 34.3M, Q2/2024:58215000 58.2M

Quarterly Net worth Q3/2025:-31333000 -31.3M, Q2/2025:-12725000 -12.7M, Q1/2025:-40455000 -40.5M, Q3/2024:-29524000 -29.5M, Q2/2024:-61925000 -61.9M

Fund house & investment objective

Company Information Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Organisation Drug Manufacturers - Specialty & Generic

Employees 304

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Sheldon L. Koenig M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow